ScripIt’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l
ScripOnly days after announcing a plan to reduce expenses by $1bn, Biogen, Inc. reeled in the third-largest biopharma M&A deal of 2023, agreeing to pay $7.3bn on 28 July for Reata Pharmaceuticals, Inc.
ScripThe market for initial public offerings in the US was vastly different in the first quarter of 2020 than it was during the same period of 2021. Uncertainty related to COVID-19 shut down global financi